Modulation of forkhead box O1A expression

Details Modulation of forkhead box O1A expression Modulation of forkhead box O1A expression

2007-04-23

2010-10-05

Chong, Kimberly (Department: 1635)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

C536S024500, C536S024310, C536S024100

Reexamination Certificate

active

07807649

ABSTRACT:
Antisense compounds, compositions and methods are provided for modulating the expression of forkhead box O1A. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding forkhead box O1A. Methods of using these compounds for modulation of forkhead box O1A expression and for treatment of diseases associated with expression of forkhead box O1A are provided, in particular, for methods of treating diabetes.

REFERENCES:
patent: 5576302 (1996-11-01), Cook et al.
patent: 5650278 (1997-07-01), Barr et al.
patent: 5670317 (1997-09-01), Ladanyi et al.
patent: 5801154 (1998-09-01), Baracchini et al.
patent: 5998148 (1999-12-01), Bennett et al.
patent: 6582908 (2003-06-01), Fodor et al.
patent: 2001/0053519 (2001-12-01), Fodor et al.
patent: 2002/0142305 (2002-10-01), Chin et al.
patent: 2003/0228597 (2003-12-01), Cowsert et al.
patent: 2005/0026164 (2005-02-01), Zhou
patent: 2006/0003322 (2006-01-01), Bentwich
Anderson et al., “Genes, chromosomes, and rhabdomyosarcoma”,Genes. Chromosomes Cancer(1999) 26:275-285.
Anderson et al., “PAX3-FKHR induces morphological change and enhances cellular proliferation and invasion in rhabdomyosarcoma”,Am. J. Pathol. (2001) 159:1089-1096.
Anderson et al., “Embryonic expression of the tumor-associated PAX3-FKHR fusion protein interferes with the developmental functions of PAX3”,Proc. Natl. Acad. Sci. U.S.A. (2001) 98:1589-1594.
Anderson et al., GenBank Accession No. AF032885.
Bennicelli et al., “Mechanism for transcriptional gain of function resulting from chromosomal translocation in alveolar rhabdomyosarcoma”,Proc. Natl. Acad. Sci. U.S.A. (1996) 93:5455-5459.
Bernasconi et al., “Induction of apoptosis in rhabdomyosarcoma cells through down-regulation of PAX proteins”,Proc. Natl. Acad. Sci. U.S.A. (1996) 93:13164-13169.
Chin et al., “On the preparation of Utilization of Isolated and Purified Oligonucleotides”, Document purportedly located on a CD-ROM and contributed to the public collection of the Katherine R. Everett Law Library of the University of North Carolina on Mar. 14, 2002.
Davis et al., “Fusion genes resulting from alternative chromosomal translocations are overexpressed by gene-specific mechanisms in alveolar rhabdomyosarcoma”,Proc. Natl. Acad. Sci. U.S.A. (1997) 94:8047-8051.
Davis et al., “Structural characterization of the FKHR gene and it's rearrangement in alveolar rhabdomyosarcoma”,Hum. Mol. Genet. (1995) 4:2355-2362.
Davis et al., “Fusion of PAX7 to FKHR by the variant t(1;13)(p36;q14) translocation in alveolar rhabdomyosarcoma”,Cancer Res. (1994) 54:2869-2872.
Del Peso et al., “Regulation of the forkhead transcription factor FKHR, but not the PAX3-FKHR fusion protein, by the serine/threonine kinase Akt”,Oncogene(1999) 18:7328-7333.
Durham et al., “FKHR binds the insulin response element in the insulin-like growth factor binding protein-1 promoter”,Endocrinology(1999) 140:3140-3146.
Epstein et al., “Tumor-specific PAX3-FKHR transcription factor, but not PAX3, activates the platelet-derived growth factor alpha receptor”,Mol. Cell. Biol. (1998) 18:4118-4130.
Gajiwala et al., “Winged helix proteins”,Curr. Opin. Struct. Biol. (2000) 10:110-116.
Galili et al., “Fusion of a fork head domain gene to PAX3 in the solid tumour alveolar rhabdomyosarcoma”,Nat. Genet. (1993) 5:230-235.
Guo et al., “Phosphorylation of serine 256 by protein kinase B disrupts transactivation by FKHR and mediates effects of insulin on insulin-like growth factor-binding protein-1 promoter activity through a conserved insulin response sequence”,J. Biol. Chem. (1999) 274:17184-17192.
Margue et al., “Transcriptional modulation of the anti-apoptotic protein BCL-XL by the paired box transcription factors PAX# and PAX3/FKHR”,Oncogene(2000) 19:2921-2929.
Nakae et al., “The forkhead transcription factor Foxol (Fkhr) confers insulin sensitivity onto glucose-6-phosphatase expression”,J. Clin. Invest. (2001) 108:1359-1367.
PCT International Search Report dated Jan. 3, 2005 for application No. PCT/US03/30352.
Scheidler et al., “The hybrid PAX3-FKHR fusion protein of alveolar rhabdomyosarcoma transforms fibroblasts in culture”,Proc. Natl. Acad. Sci. U.S.A. (1996) 93:9805-9809.
Tang et al., “Negative regulation of the forkhead transcription factor FKHR by Akt”,J. Biol. Chem. (1999) 274:16741-16746.
Branch et al., “A good antisense molecule is hard to find,” TIBS (1998) 23:45-50.
Crooke et al., “Basic Principles of Antisense Therapeutics” Antisense Research and Application (1998) Chapter 1:1-50.
New England Biolabs 1998/99 Catalog (cover page and pp. 121 and 284).
Reynolds et al., “Rational siRNA design for RNA interference” Nature Biotechnology (2004) 22(3):326-330.
Sanghvi et al., “Heterocyclic Base Modifications in Nucleic Acids and Their Applications in Antisense Oligonucleotides” Antisense Research and Applications (1993) pp. 273-288.
Anderson et al., GenBank Accession No. AF032885, 1998.
Office Action for U.S. Appl. No. 10/671,074 dated Jan. 25, 2006.
Office Action for U.S. Appl. No. 10/671,074 dated Jun. 7, 2006.

Affiliated with

Also associated with

Rating

Modulation of forkhead box O1A expression does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Modulation of forkhead box O1A expression, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Modulation of forkhead box O1A expression will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4240588